

Caroline Gordon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2991074/publications.pdf>

Version: 2024-02-01

223
papers

21,877
citations

14655

66
h-index

9589

142
g-index

229
all docs

229
docs citations

229
times ranked

14534
citing authors

#	ARTICLE	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
2	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.9	1,265
3	Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 222-233.	6.7	1,111
4	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.9	868
5	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16039.	30.5	816
6	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 1997, 40, 809-813.	6.7	586
7	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
8	Anti-inflammatory and immunosuppressive drugs and reproduction. <i>Arthritis Research and Therapy</i> , 2006, 8, 209.	3.5	469
9	Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. <i>Arthritis Research and Therapy</i> , 2005, 7, R784-95.	3.5	425
10	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.9	391
11	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	1.9	370
12	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1. <i>Rheumatology</i> , 2016, 55, 1693-1697.	1.9	350
13	Population-Based Incidence and Prevalence of Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis and Rheumatology</i> , 2014, 66, 369-378.	5.6	343
14	The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. <i>Arthritis and Rheumatism</i> , 1995, 38, 551-558.	6.7	328
15	Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 685-708.	3.3	281
16	The Incidence and Prevalence of Systemic Lupus Erythematosus, 2002-2004: The Georgia Lupus Registry. <i>Arthritis and Rheumatology</i> , 2014, 66, 357-368.	5.6	269
17	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
18	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 183-190.	0.9	266

#	ARTICLE	IF	CITATIONS
19	Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 57, 972-979.	6.7	252
20	Cancer risk in systemic lupus: An updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013, 42, 130-135.	6.5	249
21	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018, 57, e1-e45.	1.9	247
22	Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2006-2015.	0.9	231
23	A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. <i>European Journal of Immunology</i> , 1994, 24, 191-195.	2.9	212
24	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-blind, Placebo-controlled Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 362-375.	5.6	189
25	Ocular manifestations of systemic lupus erythematosus. <i>Rheumatology</i> , 2007, 46, 1757-1762.	1.9	184
26	Adverse events and efficacy of TNF- α blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. <i>Rheumatology</i> , 2009, 48, 1451-1454.	1.9	173
27	Chronic therapy with recombinant tumor necrosis factor- α in autoimmune NZB/NZW F1 mice. <i>Clinical Immunology and Immunopathology</i> , 1989, 52, 421-434.	2.0	159
28	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. <i>Rheumatology</i> , 2011, 50, 982-988.	1.9	155
29	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.9	143
30	Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 211-221.	6.7	139
31	The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project. <i>Arthritis and Rheumatology</i> , 2017, 69, 1996-2005.	5.6	135
32	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part II: analgesics and other drugs used in rheumatology practice: Table 1. <i>Rheumatology</i> , 2016, 55, 1698-1702.	1.9	129
33	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. <i>Arthritis and Rheumatology</i> , 2017, 69, 2006-2017.	5.6	126
34	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. <i>Rheumatology</i> , 2013, 52, 1313-1322.	1.9	115
35	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 138-142.	0.9	115
36	Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. <i>Arthritis and Rheumatology</i> , 2021, 73, 991-996.	5.6	114

#	ARTICLE	IF	CITATIONS
37	Pregnancy and reproduction in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2011, 50, 657-664.	1.9	112
38	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , 2010, 49, 1665-1669.	1.9	111
39	Systemic lupus erythematosus: Clinical presentations. <i>Autoimmunity Reviews</i> , 2010, 10, 43-45.	5.8	108
40	Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 231-8.	2.0	108
41	Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. <i>Rheumatology</i> , 2009, 48, 1506-1511.	1.9	107
42	Prevalence and Incidence of Systemic Lupus Erythematosus in a Population-Based Registry of American Indian and Alaska Native People, 2007-2009. <i>Arthritis and Rheumatology</i> , 2014, 66, 2494-2502.	5.6	103
43	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	5.6	98
44	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 904-913.	0.7	97
45	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	2.7	97
46	British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 4113-4119.	6.7	96
47	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. <i>Arthritis and Rheumatism</i> , 2006, 55, 892-899.	6.7	95
48	Revised British Isles Lupus Assessment Group 2004 index: A reliable tool for assessment of systemic lupus erythematosus activity. <i>Arthritis and Rheumatism</i> , 2006, 54, 3300-3305.	6.7	93
49	Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. <i>Rheumatology</i> , 2015, 54, 836-843.	1.9	92
50	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , 2009, 48, 691-695.	1.9	90
51	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
52	Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. <i>Journal of Rheumatology</i> , 2010, 37, 322-329.	2.0	83
53	Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2006, 8, R120.	3.5	80
54	The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. <i>Rheumatology</i> , 2010, 49, 723-732.	1.9	79

#	ARTICLE	IF	CITATIONS
55	Primary Anti-Phospholipid Antibody Syndrome (APS). Survey of Ophthalmology, 2002, 47, 215-238.	4.0	78
56	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2013, 72, 1308-1314.	0.9	78
57	Hydroxychloroquine-related retinal toxicity. Rheumatology, 2016, 55, 957-967.	1.9	77
58	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology, 2018, 57, 470-479.	1.9	73
59	Pregnancy and rheumatic diseases. Rheumatology, 2007, 46, 1634-1640.	1.9	72
60	The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. Rheumatology, 2013, 52, 2292-2301.	1.9	72
61	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology, 2014, 53, 275-284.	1.9	71
62	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.9	70
63	Antinuclear Antibody-“Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	3.4	70
64	Causes and management of infertility in systemic lupus erythematosus. Rheumatology, 2011, 50, 1551-1558.	1.9	69
65	Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis and Rheumatism, 2009, 61, 587-592.	6.7	68
66	Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue?. Journal of Rheumatology, 2017, 44, 398.1-398.	2.0	68
67	Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index. Arthritis and Rheumatism, 2008, 58, 1784-1788.	6.7	66
68	Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives. BMJ Open, 2014, 4, e004081.	1.9	66
69	Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology, 2014, 53, 502-511.	1.9	64
70	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus. Annals of Internal Medicine, 2021, 174, 1647-1657.	3.9	64
71	Tumor necrosis factor α activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis and Rheumatism, 2007, 56, 1776-1786.	6.7	63
72	Population-based lupus registries: Advancing our epidemiologic understanding. Arthritis and Rheumatism, 2009, 61, 1462-1466.	6.7	61

#	ARTICLE	IF	CITATIONS
73	The use of alternative medical therapies in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2000, 43, 1410-1418.	6.7	60
74	Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus â€” Fulton and DeKalb Counties, Georgia, 2002â€”2016. Morbidity and Mortality Weekly Report, 2019, 68, 419-422.	15.1	59
75	The systemic lupus erythematosus Tri-Nation study: Cumulative indirect costs. Arthritis and Rheumatism, 2007, 57, 64-70.	6.7	58
76	Pregnancy and autoimmune diseases. Best Practice and Research in Clinical Rheumatology, 2004, 18, 359-379.	3.3	57
77	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	3.4	55
78	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	5.6	55
79	The LupusQoL and Associations with Demographics and Clinical Measurements in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 2273-2279.	2.0	54
80	Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Therapeutic Advances in Chronic Disease, 2010, 1, 163-175.	2.5	52
81	Managing pregnancy in inflammatory rheumatological diseases. Arthritis Research and Therapy, 2011, 13, 206.	3.5	49
82	25â€”Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort. Arthritis Care and Research, 2014, 66, 1167-1176.	3.4	49
83	Efficacy of Epratuzumab, an Antiâ€”CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome. Arthritis and Rheumatology, 2018, 70, 763-773.	5.6	49
84	Interferon-Î±-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erythematosus monocytes. Rheumatology, 2014, 53, 2249-2258.	1.9	47
85	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. Arthritis Care and Research, 2016, 68, 1505-1513.	3.4	45
86	Telemedicine in rheumatology: a mixed methods study exploring acceptability, preferences and experiences among patients and clinicians. Rheumatology, 2022, 61, 2262-2274.	1.9	45
87	In Utero Azathioprine Exposure and Increased Utilization of Special Educational Services in Children Born to Mothers With Systemic Lupus Erythematosus. Arthritis Care and Research, 2013, 65, 759-766.	3.4	44
88	Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. Rheumatology, 2007, 47, 334-338.	1.9	43
89	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. Rheumatology, 2018, 57, 14-18.	1.9	43
90	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.9	42

#	ARTICLE	IF	CITATIONS
91	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	5.6	40
92	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.9	40
93	Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 128-135.	3.4	39
94	Current challenges in the development of new treatments for lupus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 729-735.	0.9	39
95	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	5.6	39
96	The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County. <i>Arthritis Care and Research</i> , 2019, 71, 949-960.	3.4	38
97	Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. <i>Arthritis Care and Research</i> , 2019, 71, 95-103.	3.4	38
98	Quality of life and economic evaluation in SLE clinical trials. <i>Lupus</i> , 1999, 8, 645-654.	1.6	37
99	B-Cell Targeted Therapies in Systemic Lupus Erythematosus. <i>BioDrugs</i> , 2013, 27, 85-95.	4.6	37
100	Post Hoc Analysis of the Phase II/III APRIL+SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BlyS and APRIL. <i>Arthritis and Rheumatology</i> , 2017, 69, 122-130.	5.6	37
101	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	1.9	37
102	Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. <i>Journal of Rheumatology</i> , 2004, 31, 2390-4.	2.0	37
103	EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 470-476.	0.9	36
104	Systemic lupus and malignancies. <i>Current Opinion in Rheumatology</i> , 2012, 24, 177-181.	4.3	36
105	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , 2009, 48, 1548-1552.	1.9	35
106	Assessment of disease activity and quality of life in systemic lupus erythematosus – New aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 457-467.	3.3	35
107	Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. <i>BMJ Open</i> , 2019, 9, e032569.	1.9	35
108	Decreased live births in women with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 1068-1072.	3.4	34

#	ARTICLE	IF	CITATIONS
109	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	2.0	34
110	Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nature Reviews Rheumatology, 2019, 15, 391-402.	8.0	33
111	Mycophenolate Mofetil for Remission Induction in Severe Lupus Nephritis. Nephron Clinical Practice, 2005, 100, c92-c100.	2.3	32
112	Update on systemic lupus erythematosus: autoantibodies and apoptosis. Clinical Medicine, 2001, 1, 10-14.	1.9	31
113	Incidence of End-stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry. Arthritis Care and Research, 2016, 68, 357-365.	3.4	31
114	Epratuzumab for the treatment of systemic lupus erythematosus. Expert Review of Clinical Immunology, 2018, 14, 245-258.	3.0	31
115	Dietary Omega Polyunsaturated Fatty Acid Intake and Patient-reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program. Arthritis Care and Research, 2020, 72, 874-881.	3.4	31
116	Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. Rheumatology Advances in Practice, 2020, 4, rkaa006.	0.7	31
117	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. Annals of the Rheumatic Diseases, 2021, 80, 1.1-2.	0.9	31
118	Incidence and Prevalence of Systemic Lupus Erythematosus Among Arab and Chaldean Americans in Southeastern Michigan: The Michigan Lupus Epidemiology and Surveillance Program. American Journal of Public Health, 2015, 105, e74-e79.	2.7	29
119	Systemic lupus erythematosus: An update for ophthalmologists. Survey of Ophthalmology, 2016, 61, 65-82.	4.0	29
120	The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients. Rheumatology, 2012, 51, 1877-1880.	1.9	28
121	Advances in the assessment of lupus disease activity and damage. Current Opinion in Rheumatology, 2014, 26, 510-519.	4.3	28
122	American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort. Journal of Rheumatology, 2014, 41, 875-880.	2.0	28
123	Is it me? The impact of patient-physician interactions on lupus patients' psychological well-being, cognition and health-care-seeking behaviour. Rheumatology Advances in Practice, 2020, 4, rkaa037.	0.7	28
124	Challenges of ethnicity in SLE. Best Practice and Research in Clinical Rheumatology, 2009, 23, 549-561.	3.3	27
125	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 393-396.	2.0	27
126	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	6.5	27

#	ARTICLE	IF	CITATIONS
127	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	5.6	26
128	Systemic lupus erythematosus in women: Impact on family size. <i>Arthritis and Rheumatism</i> , 2008, 59, 1656-1660.	6.7	25
129	Systemic Lupus Erythematosus and Malignancies. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 497-506.	1.9	25
130	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	5.6	25
131	A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves' disease: Comment on the article by Rood et al. <i>Arthritis and Rheumatism</i> , 2002, 46, 3109-3110.	6.7	24
132	New biologic therapy for systemic lupus erythematosus. <i>Current Opinion in Pharmacology</i> , 2013, 13, 405-412.	3.5	24
133	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	3.4	23
134	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. <i>Lupus Science and Medicine</i> , 2019, 6, e000344.	2.7	22
135	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	3.4	22
136	Cancer and Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 533-550.	1.9	22
137	The impact of the COVID-19 pandemic on the medical care and health-care behaviour of patients with lupus and other systemic autoimmune diseases: a mixed methods longitudinal study. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa072.	0.7	22
138	From BILAG to BILAG-based combined lupus assessment—30 years on. <i>Rheumatology</i> , 2016, 55, 1357-1363.	1.9	21
139	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018, 70, 1294-1302.	3.4	21
140	Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. <i>BMJ Open</i> , 2013, 3, e002852.	1.9	19
141	COVID-19 and shielding: experiences of UK patients with lupus and related diseases. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab003.	0.7	18
142	Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus — Michigan Lupus Epidemiology and Surveillance Program, 2014–2015. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 819-824.	15.1	18
143	Clinical trials in lupus: what have we learned so far?. <i>Rheumatology</i> , 2010, 49, 1025-1027.	1.9	17
144	The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2015, 34, 263-271.	2.2	17

#	ARTICLE	IF	CITATIONS
145	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	5.6	17
146	Pregnancy and autoimmune diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 359-379.	3.3	17
147	Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. <i>Lupus Science and Medicine</i> , 2021, 8, e000614.	2.7	17
148	Refractory multisystem sarcoidosis responding to infliximab therapy. <i>Clinical Rheumatology</i> , 2012, 31, 1013-1018.	2.2	16
149	Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies. <i>Lupus Science and Medicine</i> , 2014, 1, e000034.	2.7	16
150	Access and Cost-Related Nonadherence to Prescription Medications Among Lupus Patients and Controls: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis Care and Research</i> , 2021, 73, 1561-1567.	3.4	16
151	Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response. <i>Arthritis and Rheumatism</i> , 2008, 58, 1789-1795.	6.7	15
152	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 492-500.	2.0	15
153	Medications in pregnancy and breastfeeding. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 64, 68-76.	2.8	14
154	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021, 60, 4737-4747.	1.9	14
155	Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. <i>Rheumatology</i> , 2022, 61, 4006-4015.	1.9	14
156	Novel treatments for systemic lupus erythematosus. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 1256-64.	2.3	14
157	The BILAG-2004 systems tallyâ€”a novel way of representing the BILAG-2004 index scores longitudinally. <i>Rheumatology</i> , 2012, 51, 2099-2105.	1.9	13
158	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021, 73, 1789-1795.	3.4	13
159	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , 2018, 57, 1502-1503.	1.9	12
160	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.9	12
161	â€œBut you donâ€™t look sickâ€™: a qualitative analysis of the LUPUS UK online forum. <i>Rheumatology International</i> , 2021, 41, 721-732.	3.0	12
162	Prevalence of Mixed Connective Tissue Disease in a Population-Based Registry of American Indian/Alaska Native People in 2007. <i>Arthritis Care and Research</i> , 2017, 69, 1271-1275.	3.4	10

#	ARTICLE	IF	CITATIONS
163	Experience with a Punjabi, Urdu and Hindi rheumatology telephone helpline. Musculoskeletal Care, 2009, 7, 210-218.	1.4	9
164	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	3.4	9
165	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.9	9
166	Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus. Immunotherapy, 2014, 6, 1165-1175.	2.0	8
167	Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. Rheumatology Advances in Practice, 2019, 3, rkz021.	0.7	8
168	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	1.9	8
169	Estimation of the burden of shielding among a cross-section of patients attending rheumatology clinics with SLEâ€” data from the BSR audit of systemic lupus erythematosus. Rheumatology, 2021, 60, 1474-1479.	1.9	8
170	Chilblains in immune-mediated inflammatory diseases: a review. Rheumatology, 2022, 61, 4631-4642.	1.9	8
171	Clinical Pharmacology and Modification of Autoimmunity and Inflammation in Rheumatoid Disease. Drugs, 1994, 47, 259-285.	10.9	7
172	Anti-TNF therapy and pregnancy outcomes in women with inflammatory arthritis. Expert Review of Clinical Immunology, 2009, 5, 27-34.	3.0	7
173	BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. Rheumatology, 2021, 60, 1480-1490.	1.9	7
174	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	5.6	7
175	Medication decision-making and adherence in lupus: patientâ€”physician discordance and the impact of previous â€”adverse medical experiencesâ€”™. Rheumatology, 2022, 61, 1417-1429.	1.9	7
176	Will â€”the feeling of abandonmentâ€”™ remain? Persisting impacts of the COVID-19 pandemic on rheumatology patients and clinicians. Rheumatology, 2022, 61, 3723-3736.	1.9	6
177	Factors Involved in the Pathogenesis of Neutrophilic Vasculitis in MRL/Mp-lpr/lprMice: A Model for Human Microscopic Angiitis. Autoimmunity, 1999, 31, 133-145.	2.6	5
178	Lupus and zoster. Lancet, The, 2003, 362, 616.	13.7	5
179	Flares in patients with systemic lupus erythematosus. Rheumatology, 2021, 60, 3262-3267.	1.9	5
180	Prescribing anti-rheumatic drugs in pregnancy and breastfeedingâ€”the British Society for Rheumatology guideline scope. Rheumatology, 2021, 60, 3565-3569.	1.9	5

#	ARTICLE	IF	CITATIONS
181	Epidemiology of disease-activity related ophthalmological manifestations in Systemic Lupus Erythematosus: A systematic review. <i>Lupus</i> , 2021, 30, 2191-2203.	1.6	5
182	Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. <i>Lupus Science and Medicine</i> , 2022, 9, e000584.	2.7	5
183	Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan. <i>Trials</i> , 2020, 21, 652.	1.6	4
184	Large vessel vasculitides. <i>Medicine</i> , 2006, 34, 468-471.	0.4	3
185	Mortality in SLE. , 2013, , 666-675.		3
186	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. <i>Arthritis Care and Research</i> , 2022, 74, 1623-1630.	3.4	3
187	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	1.6	3
188	Understanding the impact of systemic lupus erythematosus on work amongst South Asian people in the UK: An explorative qualitative study. <i>Lupus</i> , 2021, 30, 1492-1501.	1.6	3
189	Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. <i>Arthritis Research and Therapy</i> , 2021, 23, 203.	3.5	3
190	Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 569-570.	0.9	2
191	Constitutional Symptoms and Fatigue in Systemic Lupus Erythematosus. , 2016, , 317-324.		2
192	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , 2017, 56, 1041-1043.	1.9	2
193	The FATIGUE-PRO: a new patient-reported outcome instrument to quantify fatigue in patients affected by systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 3329-3340.	1.9	2
194	Evaluation of the European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population Based Registry. <i>Arthritis Care and Research</i> , 0, , .	3.4	2
195	Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. <i>Rheumatology</i> , 0, , .	1.9	2
196	Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: Comment on the article by Ruperto et al. <i>Arthritis and Rheumatism</i> , 2006, 54, 2343-2344.	6.7	1
197	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017, 19, 287.	3.5	1
198	Drugs in Rheumatic Disease During Pregnancy. , 0, , 98-113.		1

#	ARTICLE	IF	CITATIONS
199	Rheumatoid Arthritis/SLE. , 0, , 267-281.		0
200	Rheumatic Disease. , 2013, , 1415-1440.		0
201	Managing Lupus Nephritis in Pregnant Women: Comment on the Article by Hahn et al. Arthritis Care and Research, 2013, 65, 1391-1392.	3.4	0
202	Malignancies in systemic lupus erythematosus. International Journal of Clinical Rheumatology, 2013, 8, 275-280.	0.3	0
203	E89.â€fThe Disease-Specific Lupusqol is Sensitive to Change In Patients with Moderate or Severe Systemic Lupus Erythematosus after Treatment of a Flare. Rheumatology, 0, , .	1.9	0
204	Malignancies in Systemic Lupus Erythematosus. , 2016, , 411-415.		0
205	Obituary for Paul Bacon. Rheumatology, 2018, 57, 943-945.	1.9	0
206	CS-07â€f...Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
207	233â€fEnhancing quality improvement capacity through the British Society for Rheumatologyâ€™s multi-region audit into the management of adults with systemic lupus erythematosus. Rheumatology, 2019, 58, .	1.9	0
208	I061â€fCancer and lupus: what are the links and what should we be looking out for?. Rheumatology, 2019, 58, .	1.9	0
209	I082â€fTo stop or not to stop? The effect of anti-rheumatic drugs in pregnancy. Rheumatology, 2019, 58, .	1.9	0
210	I095â€fManagement of lupus in pregnancy. Rheumatology, 2019, 58, .	1.9	0
211	Constitutional symptoms and fatigue in systemic lupus erythematosus. , 2021, , 351-359.		0
212	Malignancies in systemic lupus erythematosus. , 2021, , 461-467.		0
213	Malignancy risk and screening. , 2021, , 583-598.		0
214	O19â€fEasy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004. Rheumatology, 2021, 60, .	1.9	0
215	Constitutional Features of Systemic Lupus Erythematosus. , 2007, , 329-335.		0
216	Co-morbidities in Systemic Lupus Erythematosus. , 2012, , 229-249.		0

#	ARTICLE	IF	CITATIONS
217	Fertility and pregnancy in autoimmune rheumatic diseases. Indian Journal of Rheumatology, 2016, 11, 115.	0.4	0
218	1124€...Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
219	1107€...Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
220	1704€...Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
221	FC055: Effect of Atacicept on Renal Function in SLE Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
222	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	1.9	0
223	Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 0, , .	3.3	0